Barbara Cannon

Ms. Cannon brings over 25 years clinical research experience to NuSirt Sciences. She was responsible for the start-up of ClinTrials Research, one of the early Clinical Research Organizations (CROs), providing outsourced clinical research services to the pharmaceutical industry. She was responsible for initiation of Phase II-IV research activities and participated in the company’s IPO, (NASDAQ:CCRO). Her role as CEO, and Board Director at Celeris Corporation (NASDAQ:CRSC) focused on supporting complex medical device, biologic, and combination FDA product approvals.

Ms. Cannon currently serves on several healthcare and financial services boards and holds an MBA from Northwestern University.